INTERCEPT PHARMACEUTICALS, INC.
ICPTUnited States
34 filed reports · 436 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
Latest fiscal year
Filed reports
34 reports · Jun 2015 to Sep 2023Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 26 | 3,897 | Jun 2015 to Sep 2023 |
| Annual · 10-KSEC EDGAR | 8 | 3,216 | Dec 2015 to Dec 2022 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2023 Q3 | 10-Q | 2023-09-30 | 2023-11-06 | 367 | Open |
| FY2023 Q2 | 10-Q | 2023-06-30 | 2023-08-02 | 212 | Open |
| FY2023 Q1 | 10-Q | 2023-03-31 | 2023-04-27 | 217 | Open |
| FY2022 | 10-K | 2022-12-31 | 2023-03-02 | 741 | Open |
| FY2022 Q3 | 10-Q | 2022-09-30 | 2022-11-01 | 162 | Open |
| FY2022 Q2 | 10-Q | 2022-06-30 | 2022-08-03 | 134 | Open |
| FY2022 Q1 | 10-Q | 2022-03-31 | 2022-05-06 | 181 | Open |
| FY2021 | 10-K | 2021-12-31 | 2022-03-02 | 431 | Open |
| FY2021 Q3 | 10-Q | 2021-09-30 | 2021-11-03 | 182 | Open |
| FY2021 Q2 | 10-Q | 2021-06-30 | 2021-07-29 | 172 | Open |
| FY2021 Q1 | 10-Q | 2021-03-31 | 2021-05-06 | 181 | Open |
| FY2020 | 10-K | 2020-12-31 | 2021-02-25 | 401 | Open |
Financial data
436 concepts · 7,113 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial433 concepts · 6,982 facts · Oct 2012 to Sep 2023
- Cash and cash equivalents at carrying value51 · Dec 2012 to Sep 2023
- Net income loss50 · Dec 2012 to Sep 2023
- Nonoperating income expense48 · Dec 2013 to Sep 2023
- Other comprehensive income loss available for sale securities adjustment before reclassification adjustments net of tax48 · Dec 2013 to Sep 2023
- Other comprehensive income loss net of tax48 · Dec 2013 to Sep 2023
- Research and development expense48 · Dec 2013 to Sep 2023
- Stockholders equity (US GAAP)48 · Dec 2012 to Sep 2023
- Depreciation47 · Dec 2013 to Sep 2023
- Increase decrease in accounts payable and accrued liabilities47 · Dec 2013 to Sep 2023
- Increase decrease in prepaid deferred expense and other assets47 · Dec 2013 to Sep 2023
- Share based compensation47 · Dec 2013 to Sep 2023
- Share based compensation arrangement by share based payment award options outstanding number46 · Dec 2013 to Sep 2023
- Payments to acquire property plant and equipment45 · Dec 2013 to Sep 2023
- Accumulated other comprehensive income loss net of tax44 · Dec 2014 to Sep 2023
- Additional paid in capital44 · Dec 2014 to Sep 2023
- Assets44 · Dec 2014 to Sep 2023
- Assets current44 · Dec 2014 to Sep 2023
- Assets fair value disclosure44 · Dec 2014 to Sep 2023
- Cash and Cash Equivalents and Investments, Amortized Cost44 · Dec 2014 to Sep 2023
- Cash and Cash Equivalents and Investments, Fair Value Disclosure44 · Dec 2014 to Sep 2023
- Cash and Cash Equivalents and Investments, Unrealized Losses44 · Dec 2014 to Sep 2023
- Common stock par or stated value per share44 · Dec 2014 to Sep 2023
- Common stock shares authorized44 · Dec 2014 to Sep 2023
- Common stock shares issued44 · Dec 2014 to Sep 2023
Product2 concepts · 122 facts · Mar 2016 to Dec 2022
- Revenue120 · Mar 2016 to Dec 2022
- Revenue recognition sales returns reserve for sales returns2 · Sep 2017 to Dec 2017
Geography1 concept · 9 facts · Dec 2016 to Mar 2019
- Revenue9 · Dec 2016 to Mar 2019
Segments
131 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis2 members · 83 facts
- Product [Member]69 · Dec 2017 to Dec 2022
- License [Member]14 · Dec 2017 to Sep 2020
Product or serviceus-gaap:ProductOrServiceAxis3 members · 39 facts
- Product [Member]30 · Mar 2016 to Mar 2019
- License [Member]5 · Dec 2016 to Mar 2019
- Ocaliva [Member]4 · Sep 2016 to Dec 2017
Statement geographical2 members · 9 facts
- United States [Member]5 · Dec 2016 to Mar 2019
- Non-US [Member]4 · Dec 2017 to Mar 2019
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of INTERCEPT PHARMACEUTICALS, INC. (ICPT) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.